Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,554 questions in 140 reviews · Heart
current versionsNo studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exercise‐based cardiac rehabilitation vs usual care All‐cause mortality · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane | RR 0.93 [0.71, 1.21] | 34 studies · 3941 participants | Low |
Exercise‐based cardiac rehabilitation vs usual care All‐cause hospital admissions · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane | RR 0.69 [0.56, 0.86] | 23 studies · 2283 participants | Moderate |
Exercise‐based cardiac rehabilitation vs usual care HF‐related hospital admissions · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane | RR 0.82 [0.49, 1.35] | 10 studies · 911 participants | Moderate |
Exercise‐based cardiac rehabilitation vs usual care HRQoL (MLWHF only) · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane | no estimate extracted | 21 studies · 2699 participants | Moderate |
Exercise‐based cardiac rehabilitation vs usual care HRQoL (all measurement scales) · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane | no estimate extracted | 33 studies · 4769 participants | Very low |
Prophylactic corticosteroids vs placebo or no corticosteroids All‐cause mortality (during the index hospital admission, or within 30 days, at the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | RR 0.9 [0.75, 1.07] | 25 studies · 14940 participants | Low |
Prophylactic corticosteroids vs placebo or no corticosteroids Cardiac complications (as defined by study authors, including cardiac compromise and fatal and non‐fatal myocardial infarction, defined as ECG changes, echocardiological changes, or disproportionate elevation of troponins, during the index hospita... · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | RR 1.16 [1.04, 1.31] | 25 studies · 14766 participants | Low |
Prophylactic corticosteroids vs placebo or no corticosteroids Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | RR 0.88 [0.78, 0.99] | 18 studies · 13549 participants | Low |
Prophylactic corticosteroids vs placebo or no corticosteroids Infectious complications (as defined by study authors, including mediastinitis, wound infections, pneumonia, and need for antibiotic therapy, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | RR 0.84 [0.76, 0.92] | 28 studies · 14771 participants | Low |
Prophylactic corticosteroids vs placebo or no corticosteroids Gastrointestinal (GI) bleeding (as defined by study authors, including any upper and lower GI bleeding, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | RR 1.21 [0.87, 1.67] | 6 studies · 12533 participants | Low |
Prophylactic corticosteroids vs placebo or no corticosteroids Renal failure (as defined by study authors, including dialysis, creatinine rise, and oliguria, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | RR 0.84 [0.69, 1.02] | 13 studies · 12799 participants | Low |
Prophylactic corticosteroids vs placebo or no corticosteroids Length of hospital stay (measured in days, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane | no estimate extracted | 25 studies · 1841 participants | Very low |
Mobile phone text messaging vs usual care Medication adherence (self‐reported adherence, questionnaire, tablet counts, medication event monitoring systems, pharmacy prescription data) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 18 studies · 8136 participants | Very low |
Mobile phone text messaging vs usual care Fatal cardiovascular events (percentage of people having fatal cardiovascular events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | OR 0.83 [0.47, 1.45] | 4 studies · 1654 participants | Low |
Mobile phone text messaging vs usual care Non‐fatal cardiovascular events (percentage of people having non‐fatal cardiovascular events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | Very low |
Mobile phone text messaging vs usual care Combined CVD events (percentage of people having combined CVD events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | Very low |
Mobile phone text messaging vs usual care Low‐density lipoprotein cholesterol (mg/dL) (endpoint low‐density lipoprotein cholesterol reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 8 studies · 4983 participants | Very low |
Mobile phone text messaging vs usual care Blood pressure (mmHg) (endpoint blood pressure reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 8 studies · 5173 participants | Very low |
Mobile phone text messaging vs usual care Heart rate (beats per minute) (endpoint heart rate reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 4 studies · 2946 participants | Very low |
Mindfulness‐based interventions (MBIs) vs active comparators Clinical CVD events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Clinical CVD events (CVD mortality and non‐fatal MI) · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | RR 0.94 [0.37, 2.42] | 1 study · 110 participants | Very low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 9 studies · 379 participants | Low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 9 studies · 379 participants | Low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Anxiety, change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 9 studies · 533 participants | Low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Depression, change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 15 studies · 912 participants | Low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Perceived stress, change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 11 studies · 708 participants | Low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Well‐being · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 2 studies · 198 participants | Moderate |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Adverse events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | RR 5 [0.27, 91.52] | 1 study · 18 participants | Low |
Mindfulness‐based interventions (MBIs) vs non‐active comparators Smoking cessation · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | RR 1.36 [0.86, 2.13] | 2 studies · 453 participants | Low |
Transcendental meditation (TM) vs active comparators Clinical CVD events (CVD mortality, non‐fatal MI and stroke, revascularisations) · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | RR 0.91 [0.56, 1.49] | 1 study · 201 participants | Low |
Mindfulness‐based interventions (MBIs) vs active comparators Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 6 studies · 388 participants | Low |
Transcendental meditation (TM) vs active comparators Systolic blood pressure (mmHg), change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 8 studies · 774 participants | Moderate |
Transcendental meditation (TM) vs active comparators Diastolic blood pressure (mmHg), change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 8 studies · 774 participants | Low |
Transcendental meditation (TM) vs active comparators Anxiety, change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 3 studies · 200 participants | Low |
Transcendental meditation (TM) vs active comparators Depression, change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 5 studies · 421 participants | Moderate |
Transcendental meditation (TM) vs active comparators Perceived stress, change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 3 studies · 194 participants | Very low |
Transcendental meditation (TM) vs active comparators Well‐being · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs active comparators Adverse events · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs active comparators Smoking cessation · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Clinical CVD events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 2 studies · 139 participants | Low |
Mindfulness‐based interventions (MBIs) vs active comparators Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 6 studies · 388 participants | Low |
Transcendental meditation (TM) vs non‐active comparators Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 2 studies · 139 participants | Low |
Transcendental meditation (TM) vs non‐active comparators Anxiety, change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 1 study · 112 participants | Low |
Transcendental meditation (TM) vs non‐active comparators Depression, change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 1 study · 112 participants | Low |
Transcendental meditation (TM) vs non‐active comparators Perceived stress · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Well‐being · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Adverse events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Smoking cessation · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐based interventions (MBIs) vs active comparators Anxiety, change from baseline · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | 9 studies · 438 participants | Moderate |